Martin Kaul, Peter End, Maciej Cabanski, Carole Schuhler, Annamaria Jakab, Magdalena Kistowska, . . . Bruno Cenni. (2021). Remibrutinib (LOU064): A selective potent oral BTK inhibitor with promising clinical safety and pharmacodynamics in a randomized phase I trial. Wiley.
Chicagoスタイル(17版)引用形式Martin Kaul, et al. Remibrutinib (LOU064): A Selective Potent Oral BTK Inhibitor with Promising Clinical Safety and Pharmacodynamics in a Randomized Phase I Trial. Wiley, 2021.
MLA(9版)引用形式Martin Kaul, et al. Remibrutinib (LOU064): A Selective Potent Oral BTK Inhibitor with Promising Clinical Safety and Pharmacodynamics in a Randomized Phase I Trial. Wiley, 2021.
警告: この引用は必ずしも正確ではありません.